Featured Research

from universities, journals, and other organizations

Aggressive blood cancer: Clinical trial of lenalidomide plus dexamethasone followed by autologous stem cell transplantation (ASCT) in multiple myeloma

Date:
December 7, 2010
Source:
John Theurer Cancer Center
Summary:
A new transplantation technique, which uses a patient's own adult stem cells, has been a first-line treatment for patients who are newly diagnosed with certain blood cancers. Multiple myeloma is a cancer that attacks plasma cells, which protect the body against disease and infection. For patients under the age of 65 who survived four cycles of treatment, overall survival at three years was 94 percent with early stem cell transplantation, vs. 78 percent for those who continued to receive a drug regimen instead.

As lead author of a study by the Eastern Cooperative Oncology Group (ECOG), David S. Siegel, M.D., Ph.D., Co-Chief of Multiple Myeloma at the John Theurer Center, retrospectively analyzed data from the ECOG E4A03 trial. The earlier trial tested combination therapies for newly diagnosed multiple myeloma patients.

"We wanted to look at the effect of early autologous peripheral blood stem cell transplantation," said Dr. Siegel. "Transplantation in early-stage myeloma has become controversial because combination therapies with lenalidomide and dexamethasone have been shown to dramatically improve outcomes."

This transplantation technique, which uses a patient's own adult stem cells, has been a first-line treatment for patients who are newly diagnosed with this blood cancer. Multiple myeloma is a cancer that attacks plasma cells, which protect the body against disease and infection. It currently has a very poor prognosis.

Patients in the study were randomized to receive either lenalidomide with high-dose dexamethasone or lenalidomide with low-dose dexamethasone. After four rounds of treatment, patients had the option of continuing with drug therapy or receiving a stem cell transplant. For patients under the age of 65 who survived four cycles of treatment, overall survival at three years was 94 percent with early stem cell transplantation, vs. 78 percent for those who continued to receive a drug regimen instead.

"This analysis shows that the strategy of combining these medications followed by early adult stem cell transplantation has a remarkably good outcome and supports the continued role of early transplantation in the newly diagnosed," said Dr. Siegel. "Additional randomized trials on the timing of ASCT in myeloma may provide more answers on optimal treatment strategies."

This research was presented at the annual meeting of the American Society of Hematology (ASH) taking place December 4-7, 2010 in Orlando, Florida.


Story Source:

The above story is based on materials provided by John Theurer Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

John Theurer Cancer Center. "Aggressive blood cancer: Clinical trial of lenalidomide plus dexamethasone followed by autologous stem cell transplantation (ASCT) in multiple myeloma." ScienceDaily. ScienceDaily, 7 December 2010. <www.sciencedaily.com/releases/2010/12/101207125852.htm>.
John Theurer Cancer Center. (2010, December 7). Aggressive blood cancer: Clinical trial of lenalidomide plus dexamethasone followed by autologous stem cell transplantation (ASCT) in multiple myeloma. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2010/12/101207125852.htm
John Theurer Cancer Center. "Aggressive blood cancer: Clinical trial of lenalidomide plus dexamethasone followed by autologous stem cell transplantation (ASCT) in multiple myeloma." ScienceDaily. www.sciencedaily.com/releases/2010/12/101207125852.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins